AR121804A1 - Preparación sólida y método para producir la misma - Google Patents

Preparación sólida y método para producir la misma

Info

Publication number
AR121804A1
AR121804A1 ARP210100940A ARP210100940A AR121804A1 AR 121804 A1 AR121804 A1 AR 121804A1 AR P210100940 A ARP210100940 A AR P210100940A AR P210100940 A ARP210100940 A AR P210100940A AR 121804 A1 AR121804 A1 AR 121804A1
Authority
AR
Argentina
Prior art keywords
mass
parts
solid preparation
producing
granule
Prior art date
Application number
ARP210100940A
Other languages
English (en)
Spanish (es)
Inventor
Rie Yamada
Hazuki Omagari
Toshinori Tanaka
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of AR121804A1 publication Critical patent/AR121804A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP210100940A 2020-04-10 2021-04-09 Preparación sólida y método para producir la misma AR121804A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020071233 2020-04-10

Publications (1)

Publication Number Publication Date
AR121804A1 true AR121804A1 (es) 2022-07-13

Family

ID=78023633

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100940A AR121804A1 (es) 2020-04-10 2021-04-09 Preparación sólida y método para producir la misma

Country Status (4)

Country Link
JP (2) JP6989064B1 (ja)
AR (1) AR121804A1 (ja)
TW (1) TW202203924A (ja)
WO (1) WO2021206159A1 (ja)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310203A (en) * 2015-12-02 2024-03-01 Nippon Shinyaku Co Ltd Pharmaceutical preparation containing 2-{4-[N-(6,5-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
US11382912B2 (en) * 2017-11-16 2022-07-12 Nippon Shinyaku Co., Ltd. Controlled-release preparation
MX2020008695A (es) * 2018-02-21 2020-09-25 Nippon Shinyaku Co Ltd Composicion granular, metodo de produccion para composicion granular y metodo para mejorar la propiedad de disolucion para composicion granular.

Also Published As

Publication number Publication date
TW202203924A (zh) 2022-02-01
WO2021206159A1 (ja) 2021-10-14
JP2022016561A (ja) 2022-01-21
JP6989064B1 (ja) 2022-01-05
JPWO2021206159A1 (ja) 2021-10-14

Similar Documents

Publication Publication Date Title
AU2007298751B2 (en) Pharmaceutical compositions containing rosuvastatin calcium
KR102072371B1 (ko) 7-[4-(4-벤조[ｂ]티오펜-4-일-피페라진-1-일)부톡시]-1Ｈ-퀴놀린-2-온 또는 그 염을 함유하는 정제
BRPI0607869A2 (pt) hidroxietilcelulose em bloco, derivados da mesma, processos de fabricação e usos da mesma
BRPI0518553A2 (pt) composiÇço farmacÊutica estÁvel, mÉtodo para estabilizaÇço de pelo menos um ingrediente farmaceuticamente ativo e mÉtodo de uso de celulose microcristalina silicificada
DOP2022000110A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
EA201100595A1 (ru) Фармацевтическая композиция 514
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
EA201992074A1 (ru) Фармацевтическая композиция, содержащая селексипаг
BR112021022335A2 (pt) Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
BR112021024325A2 (pt) Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
BR112022002496A2 (pt) Compostos deuterados para uso no tratamento de câncer
HN2008000240A (es) Agentes voluminizadores
BR112022019057A2 (pt) Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune
AR121804A1 (es) Preparación sólida y método para producir la misma
CL2022000723A1 (es) Composiciones de recubrimiento de semillas
BR112022020609A2 (pt) Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo
CO2023005942A2 (es) Composiciones farmacéuticas de un inhibidor de cinasa
PE20100471A1 (es) Composicion de liberacion pulsatil de sildenafil y proceso para prepararla
ECSP20057951A (es) Composición granular, método de producción para composición granular y método de mejora de la propiedad de disolución para composición granular
KR20240010065A (ko) 엠파글리플로진 공결정을 함유하는 약제학적 조성물
FI3737470T3 (fi) 3-fenyyli-4-heksyylihappojohdannaisia GPR40-agonisteina
RU2013130309A (ru) Твердая молекулярная дисперсия
HRP20130225T1 (hr) Formulacija s odgođenim otpuštanjem koja sadrži 3-(2-dimetilaminometilcikloheksil) fenol
BR112022014772A2 (pt) Dispersão sólida amorfa, composição farmacêutica e processos para a preparação destas